Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05822219 · ClinicalTrials.gov registry record · NA

Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases

A NA study of COVID-19 and Rheumatic Diseases, sponsored by Northwestern University.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05822219 is a NA study of COVID-19 and Rheumatic Diseases that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 60 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05822219, a NA study of COVID-19 and Rheumatic Diseases, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

To establish the efficacy of a community-based POL (Popular Opinion Leader) intervention with two different trainings designed to increase COVID-19 vaccine and booster uptake and reduce hesitancy among social networks of Black individuals with rheumatic conditions. The investigators will also determine the structure and composition of the personal and outreach social networks of POLs.

Interventions

  • BEHAVIORAL COVID-19 vaccine and booster training, and importance

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-03-15
Est. Completion 2027-03-30
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT05822219

The ClinicalTrials.gov registry entry for NCT05822219 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which COVID-19 vaccine and booster training, and importance is the first listed.

NCT05822219 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05822219 about?

NCT05822219 is a clinical study titled "Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases". To establish the efficacy of a community-based POL (Popular Opinion Leader) intervention with two different trainings designed to increase COVID-19 vaccine and booster uptake and reduce hesitancy among social networks of Black individuals with rheumatic conditions. The investigators will also determ...

What is the current status of trial NCT05822219?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-03-15. Estimated completion is 2027-03-30.

What conditions does trial NCT05822219 study?

This clinical trial studies the following conditions: COVID-19, Rheumatic Diseases, SLE, COVID-19 Vaccine.

What interventions are being tested in trial NCT05822219?

The interventions under investigation include: COVID-19 vaccine and booster training, and importance (BEHAVIORAL).

Who is sponsoring clinical trial NCT05822219?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05822219 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.